Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2401263 | 0.78 | CYP1A2 (0.49) | PDE10AHIF1A | |
| Hydrochloric Acid SCHEMBL7512828 | 0.77 | ALDH1A1 (0.41) | KDM4EMEN1KMT2AALDH1A1PDE10A | |
| Hydrochloric Acid SCHEMBL8071622 | 0.77 | CYP1A2 (0.47) | PDE10A | |
| SCHEMBL22104646 | 0.75 | ALDH1A1 (0.43) | KDM4ELMNAMEN1KMT2ASUCNR1 | |
| Bromide SCHEMBL4485285 | 0.75 | CYP1A2 (0.49) | PDE10AHIF1A | |
| SCHEMBL514723 | 0.74 | SUCNR1 (0.43) | KDM4ELMNAMEN1KMT2ASUCNR1 | |
| SCHEMBL4823229 | 0.73 | ALDH1A1 (0.48) | KDM4ELMNAMEN1KMT2ASUCNR1 | |
| Hydrochloric Acid SCHEMBL136776 | 0.73 | GRIN2D (0.52) | KDM4EALDH1A1APPHIF1AMAPT | |
| SCHEMBL2009161 | 0.72 | CCR1 (0.48) | KDM4ELMNAMEN1KMT2ASUCNR1 | |
| SCHEMBL7514147 | 0.72 | ALDH1A1 (0.47) | KDM4ELMNAMEN1KMT2ASUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2576540-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | KDM4E 202/4885LMNA 3470/4885MEN1 3391/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | KDM4E 969/4885LMNA 2445/4885MEN1 3126/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | KDM4E 1397/4885LMNA 3129/4885MEN1 2701/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | KDM4E 969/4885LMNA 2445/4885MEN1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.